CureVac and MD Anderson Collaborate on Innovative Cancer Vaccines

CureVac N.V., a global biopharmaceutical company, and The University of Texas MD Anderson Cancer Center announced a partnership to develop mRNA-based cancer vaccines. This strategic alliance combines CureVac’s extensive experience in mRNA technology with MD Anderson’s expertise in cancer research, focusing on vaccines for hematological and solid tumors with unmet medical needs.

The collaboration aims to accelerate the development of off-the-shelf cancer vaccines by utilizing cutting-edge technologies for cancer antigen identification and validation. MD Anderson will conduct early-stage clinical trials, while CureVac retains the rights to further develop and commercialize the vaccine candidates globally.

Both institutions have committed to leveraging their respective technologies and resources to advance these novel therapeutic options. Initial activities will center around selecting high-potential vaccine candidates and obtaining regulatory approvals for clinical studies. CureVac’s CEO, Dr. Alexander Zehnder, emphasized the potential of this cooperation to enhance patient outcomes significantly.